Andrew D Barreto1, Christopher V Fanale2, Andrei V Alexandrov3, Kevin C Gaffney4, Farhaan S Vahidy1, Claude B Nguyen5, Amrou Sarraj1, Mohammad Rahbar6, James C Grotta7, Sean I Savitz1. 1. Department of Neurology, Stroke Program; University of Texas Health Science Center at Houston, Houston, TX. 2. Colorado Research Institute, Englewood, CO. 3. Department of Neurology, Stroke Program; University of Tennessee, Memphis, TN. 4. Memorial Hermann Hospital-The Woodlands, The Woodlands, TX. 5. Department of Neurology, University of Pennsylvania Hospital, Philadelphia, PA. 6. A) Division of Clinical and Translational Sciences, Department of Internal Medicine, University of Texas Medical School at Houston, Houston, TX, B) Division of Epidemiology, Human Genetics, and Environmental Sciences (EHGES), University of Texas School of Public Health at Houston, Houston, TX, and C) Biostatistics/Epidemiology/Research Design (BERD) Component, Center for Clinical and Translational Sciences (CCTS), University of Texas Health Science Center at Houston, Houston, TX. 7. Clinical Innovation and Research Institute, Memorial Hermann Hospital-Texas Medical Center, Houston, TX.
Abstract
OBJECTIVE: It is estimated that one of four ischemic strokes are noticed upon awakening and are not candidates for intravenous recombinant tissue plasminogen activator (rtPA) because their symptoms are >3 hours from last seen normal (LSN). We tested the safety of rtPA in a multicenter, single-arm, prospective, open-label study (NCT01183533) in patients with wake-up stroke (WUS). METHODS: We aimed to enroll 40 WUS patients with disabling deficits. Patients were 18 to 80 years of age, National Institutes of Health Stroke Scale (NIHSS) ≤25, and selected only on the appearance of noncontrast computed tomography (ie, over one-third middle cerebral artery territory hypodensity). Standard-dose (0.9mg/kg) intravenous rtPA had to be started ≤3 hours of patient awakening. The primary safety outcome was symptomatic intracerebral hemorrhage (sICH) with preplanned stopping rules and data safety board oversight. Other endpoints included: asymptomatic intracerebral hemorrhage; clinical improvement in NIHSS; and 90-day modified Rankin Scale (mRS) score. RESULTS: Between October 2010 and October 2013, all 40 preplanned patients were enrolled (50% men) at five stroke centers. Four patients (10%) were subsequently determined to be mimics. Patients had a mean age of 60.8, median NIHSS of 6.5 (range, 2-24), and received thrombolysis at a mean time of 10.3 ± 2.6 LSN and 2.6 ± 0.6 hours from awakening with deficits. No sICH or parenchymal hematomas occurred. At 3 months, 20 of 38 (52.6%) patients achieved excellent recovery with mRS scores of 0 or 1 (2 patients were lost to follow-up). INTERPRETATION: Intravenous thrombolysis was safe in this prospective WUS study of patients selected by noncontrast CT. A randomized effectiveness trial appears feasible using a similar, pragmatic design. Ann Neurol 2016;80:211-218.
OBJECTIVE: It is estimated that one of four ischemic strokes are noticed upon awakening and are not candidates for intravenous recombinant tissue plasminogen activator (rtPA) because their symptoms are >3 hours from last seen normal (LSN). We tested the safety of rtPA in a multicenter, single-arm, prospective, open-label study (NCT01183533) in patients with wake-up stroke (WUS). METHODS: We aimed to enroll 40 WUS patients with disabling deficits. Patients were 18 to 80 years of age, National Institutes of Health Stroke Scale (NIHSS) ≤25, and selected only on the appearance of noncontrast computed tomography (ie, over one-third middle cerebral artery territory hypodensity). Standard-dose (0.9mg/kg) intravenous rtPA had to be started ≤3 hours of patient awakening. The primary safety outcome was symptomatic intracerebral hemorrhage (sICH) with preplanned stopping rules and data safety board oversight. Other endpoints included: asymptomatic intracerebral hemorrhage; clinical improvement in NIHSS; and 90-day modified Rankin Scale (mRS) score. RESULTS: Between October 2010 and October 2013, all 40 preplanned patients were enrolled (50% men) at five stroke centers. Four patients (10%) were subsequently determined to be mimics. Patients had a mean age of 60.8, median NIHSS of 6.5 (range, 2-24), and received thrombolysis at a mean time of 10.3 ± 2.6 LSN and 2.6 ± 0.6 hours from awakening with deficits. No sICH or parenchymal hematomas occurred. At 3 months, 20 of 38 (52.6%) patients achieved excellent recovery with mRS scores of 0 or 1 (2 patients were lost to follow-up). INTERPRETATION: Intravenous thrombolysis was safe in this prospective WUS study of patients selected by noncontrast CT. A randomized effectiveness trial appears feasible using a similar, pragmatic design. Ann Neurol 2016;80:211-218.
Authors: Lee H Schwamm; Ona Wu; Shlee S Song; Lawrence L Latour; Andria L Ford; Amie W Hsia; Alona Muzikansky; Rebecca A Betensky; Albert J Yoo; Michael H Lev; Gregoire Boulouis; Arne Lauer; Pedro Cougo; William A Copen; Gordon J Harris; Steven Warach Journal: Ann Neurol Date: 2018-04-27 Impact factor: 10.422
Authors: Victor C Urrutia; Roland Faigle; Steven R Zeiler; Elisabeth B Marsh; Mona Bahouth; Mario Cerdan Trevino; Jennifer Dearborn; Richard Leigh; Susan Rice; Karen Lane; Mustapha Saheed; Peter Hill; Rafael H Llinas Journal: PLoS One Date: 2018-05-22 Impact factor: 3.240
Authors: Aldo A Mendez; Edgar A Samaniego; Sunil A Sheth; Sudeepta Dandapat; David M Hasan; Kaustubh S Limaye; Bradley J Hindman; Colin P Derdeyn; Santiago Ortega-Gutierrez Journal: Crit Care Res Pract Date: 2018-06-28
Authors: Devin L Brown; Chengwei Li; Ronald D Chervin; Erin Case; Nelda M Garcia; Susan D Tower; Lynda D Lisabeth Journal: Neurol Clin Pract Date: 2018-02